Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
AbbVie (prior sponsor, Abbott)
With
Veeda Clinical Research
This study was designed as a non-interventional observational study. Kaletra was prescribed in the usual manner in accordance with the terms of the local market authorization with regards to dose, population and indication as well as local guidelines.
Age
18–99
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Patients with HIV infection
Patients that will be treated with Kaletra tablets independent from their participation in this study
You may not be if
Hypersensitivity against Kaletra or other ingredients
Severe liver insufficiency
No concommitant astemizole, terfenadine, oral midazolam, triazolam, cisapride, pimozide, amiodarone, ergotamine, dihydroergotamine, ergometrine, methylergometrine, vardenafil and St. John's wort
Patients who received more than 1 protease inhibitor during their therapy history
Clareo Health | Study on the Usage, Dosing, Tolerability, and Effectiveness of Kaletra Tablet
